Search
Gestrinone
go.drugbank.com/drugs/DB11619Approvedis used primarily in the treatment of endometriosis. … Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America.
Tilactase
go.drugbank.com/drugs/DB13761ApprovedInvestigationalTilactase is a beta-D-galactosidase obtained from _Aspergillus oryzae_. It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal. … [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338]
Floxuridine
go.drugbank.com/drugs/DB00322ApprovedInvestigationalIt has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. … When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate.
Fospropofol
go.drugbank.com/drugs/DB06716ApprovedIllicitInvestigationalWithdrawnFospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.
Defactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigational[L53208,A273943] Defactinib was approved by the US FDA in May 2025 in a co-package alongside [avutometinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian … resistance mechanism to MAPK inhibitors, facilitating tumor cell proliferation and survival in the absence of MAPK signaling.
Synonyms: N-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamideIcotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIcotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]
Zanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigationalZanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[ … In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada.
Imiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. … Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production.
Fluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigationalFluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. … [A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body.
Methacholine
go.drugbank.com/drugs/DB06709ApprovedAsthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing … [L31763] In patients with AHR, a lower dose of methacholine is required to induce bronchoconstriction, which forms the basis for the methacholine challenge test to diagnose AHR.